title: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
abstract: Nevirapine (NVP) single dose is widely used in developing countries to prevent HIV-1 mother-to-child transmission. However, this regimen selects key drug resistance mutations that can impair further HAART efficacy. We studied the HIV-1 reverse transcriptase genotype from 29 Ivoirian women 1 month after an NVP single-dose prophylaxis. NVP resistance mutations were observed in six (20.7%) women. The majority of the isolates were CRF02_AG. These results confirm previous studies and suggest the need for different prophylaxis regimens in this setting.
authors.affiliation: Centre Intégré de Recherches Biocliniques d'Abidjan, Abidjan, Côte d'Ivoire. ta_toni@yahoo.com
authors.forename: Thomas D'Aquin
authors.initials: TD
authors.lastname: Toni
authors.forename: Bernard
authors.initials: B
authors.lastname: Masquelier
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Lazaro
authors.forename: Mireille
authors.initials: M
authors.lastname: Dore-Mbami
authors.forename: Franck-Olivier
authors.initials: FO
authors.lastname: Ba-Gomis
authors.forename: Yacine
authors.initials: Y
authors.lastname: Téa-Diop
authors.forename: Kouadio
authors.initials: K
authors.lastname: Kouakou
authors.forename: Joseph
authors.initials: J
authors.lastname: Diby
authors.forename: Evelyne
authors.initials: E
authors.lastname: Sia
authors.forename: Sylvie
authors.initials: S
authors.lastname: Soppi
authors.forename: Samuel
authors.initials: S
authors.lastname: Essien
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Schrive
authors.forename: Patricia
authors.initials: P
authors.lastname: Pinson
authors.forename: Henri
authors.initials: H
authors.lastname: Chenal
authors.forename: Hervé J
authors.initials: HJ
authors.lastname: Fleury
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018890:Chemoprevention; D007560:Cote d'Ivoire; D004279:DNA, Viral / Q000032:analysis; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008969:Molecular Sequence Data; D009154:Mutation; D019829:Nevirapine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010802:Phylogeny; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017422:Sequence Analysis, DNA
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D054303:HIV Reverse Transcriptase